Impact of COVID-19 on Substance Use Disorder Treatment: Examining the Influence of In-Person and Telehealth Intervention on Outcomes Using Real-World Data.

Impact of COVID-19 on Substance Use Disorder Treatment: Examining the Influence of In-Person and Telehealth Intervention on Outcomes Using Real-World Data.

Publication date: Jan 06, 2025

Background: The COVID-19 health crisis challenged healthcare systems around the world, leading to restrictions in access to face-to-face healthcare services, and forcing rapid adaptation to telehealth services. At present, there is a gap in the functioning of this adaptation in drug-dependence centres. The present study analyses, over four years, care indicators on the care modality (face-to-face vs. hybrid), the patient profile and the impact on retention in treatment. Methods: Retrospective observational study with data collected between 14 March 2019 and 21 June 2023. The electronic health records of 44,930 patients were analysed according to different moments and selected based on the different health measures imposed by the COVID-19 pandemic. Patients were classified according to whether they received an in-person or hybrid intervention. Bivariate statistics and logistic regression analysis were applied. Results: The trend over time shows an increase in the number of patients seen in addiction centres. However, no notable changes within the in-person care modality and a modest increase in telehealth services are observed. Telehealth is primarily used among patients with opiate addiction, as well as with those with comorbid mental disorders. Logistic regression analysis shows that patients in a hybrid modality are more likely to remain in treatment. Conclusions: Results show that hybrid care is associated with higher patient retention rates. Despite this, different profiles are mostly treated with in-person interventions rather than hybrid modalities. Future studies should explore how to generalise personalised hybrid care among SUD patients considering factors such as patients’ educational level, employment status or accessibility to mental health services.

Open Access PDF

Concepts Keywords
Basel COVID-19
Forcing hybrid treatments
Healthcare outcomes
June retention
Statistics substance use

Semantics

Type Source Name
disease MESH COVID-19
disease MESH Substance Use Disorder
disease IDO intervention
disease MESH opiate addiction
disease MESH mental disorders
disease MESH educational level
disease MESH scar
drug DRUGBANK Cysteamine
disease MESH privacy
disease IDO history
drug DRUGBANK Aspartame
disease IDO country
disease IDO process
drug DRUGBANK Methionine
disease MESH nicotine dependence
drug DRUGBANK Medical Cannabis
disease MESH alcohol dependence
disease MESH pathological gambling
disease MESH cocaine dependence
disease MESH cannabis dependence
disease MESH psychotic disorders
disease MESH mood disorders
disease MESH anxiety disorders
disease MESH personality disorders
drug DRUGBANK Ethanol
drug DRUGBANK Cocaine
disease MESH anxiety
disease MESH Psychotic Mood disorders
drug DRUGBANK Etoperidone
disease IDO quality
disease MESH relapses
disease MESH tics
drug DRUGBANK Spinosad
drug DRUGBANK Coenzyme M
disease MESH dementia
drug DRUGBANK Buprenorphine
drug DRUGBANK Diamorphine
drug DRUGBANK Trestolone
drug DRUGBANK Allylestrenol
drug DRUGBANK Minaprine
disease MESH Posttraumatic Stress Disorder
disease MESH dual diagnosis
drug DRUGBANK Carboxyamidotriazole

Original Article

(Visited 2 times, 1 visits today)